Rimonabant in rats with a metabolic syndrome: Good news after the depression

British Journal of Pharmacology

Volumn 154, Issue 5, 2008, Pages 915-917

  Di Marzo, V ^a   Szallasi, A ^b  

^a CNR   (Italy)

^b MONMOUTH MEDICAL CENTER   (United States)

Author keywords

Cannabinoid CB 1 receptor antagonist; Platelet activation; Pro inflammatory cytokines RANTES and MCP1; Rimonabant

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADENOSINE DIPHOSPHATE; ADIPOCYTOKINE; ADIPONECTIN; CANNABINOID 2 RECEPTOR; FIBRINOGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RANTES; RIMONABANT; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

ABDOMINAL OBESITY; ACUTE HEART INFARCTION; ADIPOGENESIS; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MONOCYTE; NEUTROPHIL COUNT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; ZUCKER RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; DEPRESSION; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; LEUKOCYTES; METABOLIC SYNDROME X; PIPERIDINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; RATS; RATS, ZUCKER; RECEPTOR, CANNABINOID, CB1;

EID: 46249102927     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.170     Document Type: Note

References (12)

1. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V (2001). The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 276: 12856-12863.
2. Després JP, Lemieux I (2006). Abdominal obesity and metabolic syndrome. Nature 444: 881-887.
3. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C et al. (2007). Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46: 122-129.
4. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W (2008). Increased energy expenditure contributes more to the body weight reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats. Endocrinology; e-pub ahead of print.
5. Lean M, Gruer L, Alberti G, Sattar N (2006). ABC of obesity. Obesity - can we turn the tide? BMJ 333: 1261-1264.
6. Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW et al. (2008). Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol 153: 226-239.
7. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agrò A (2001). Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 268: 819-825.
8. Matias I, Di Marzo V (2007). Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18: 27-37.
9. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Huffman JW et al. (2007). CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293: H2210-H2218.
10. Schäfer A, Pfrang J, Neumüller J, Fiedler S, Ertl G, Bauersachs J (2008). The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 154: 1047-1054 (this issue).
11. Suri A, Szallasi A (2008). The emerging role of TRPV1 in diabetes and obesity. Trends Pharmacol Sci 29: 29-36.
12. Van Gaal L, Pi-Sunyer X, Despres J-P, McCarthy C, Scheen A (2008). Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients. Pooled 1-year data from the Riomonabant in Obesity (RIO) program. Diabetes Care 31 (Supplement 2): S229-S240.